数据
资源
版本对比
免费注册
预约演示
免费注册
Otsuka and Lundbeck Present Results from Three Clinical Trials of
Brexpiprazole
in Combination with
Sertraline
for the Treatment of
Post-Traumatic Stress Disorder (PTSD)
in Adults
2024-05-28
·
BioSpace
临床结果
上市批准
临床3期
ASCO会议
These data represent one of the largest clinical development programs to date for adults living with
PTSD
and a significant development in a therapy area that hasn’t seen a new approval for a pharmacological treatment in more than 20 years.1,2,3 These data showed that
brexpiprazole
in combination with
sertraline
improved symptoms of
PTSD
in two out of the three studies, based on the primary endpoint of change in CAPS-5 total scores from Week 1 to Week 10 compared to
sertraline
plus placebo.1
Brexpiprazole
in combination with
sertraline
was associated with greater improvements across the four symptom clusters of
PTSD
(re-experiencing, avoidance, negative cognition/mood and arousal/reactivity symptoms), compared to
sertraline
plus placebo.4 No new safety observations related to
brexpiprazole
were identified.2 Based on these data,
Otsuka
and
Lundbeck
submitted a supplemental New Drug Application (sNDA) in April to the
U.S.
Food and Drug Administration (FDA)
for
brexpiprazole
in combination with
sertraline
for the treatment of adults living with
PTSD
. PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--
Otsuka Pharmaceutical Development & Commercialization, Inc.
(
Otsuka
) and Lundbeck Pharmaceuticals LLC (
Lundbeck
) today presented results from the Phase II (Trial 061) and Phase III trials (Trial 071 and 072) evaluating the safety and efficacy of
brexpiprazole
in combination with
sertraline
for the treatment of adults with
post-traumatic stress disorder
(PTSD).1,2 The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami. This press release features multimedia. View the full release here: The primary endpoint for all three trials was the change from Week 1 to Week 10 in the CAPS-5 total score for
brexpiprazole
and
sertraline
combination therapy versus
sertraline
plus placebo in patients diagnosed with
PTSD
according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).1 The trials were randomized, double blind, active-controlled, and Trial 061 and 071 were flexible dose trials, while Trial 072 was a fixed dose trial.1 In Trial 061 and 071,
brexpiprazole
in combination with
sertraline
was associated with a statistically significant reduction (p<0.05) in
PTSD
symptoms compared to
sertraline
plus placebo, as measured by the change in the Clinician-Administered
PTSD
Scale (CAPS-5) total score from baseline to Week 10 (primary endpoint). In Trial 072, while the primary endpoint was not met, reductions in
PTSD
symptom severity with
brexpiprazole
in combination with
sertraline
were consistent with Trials 061 and 071. Improvements were consistently observed across the Clinical Global Impression Severity (CGI-S) scale and the four CAPS-5 clusters of re-experiencing, avoidance, negative cognition/mood and arousal/reactivity symptoms in Trials 061 and 071.1,4 “Only approximately half of people living with
PTSD
seek treatment, even though it is one of the most common mental health conditions in the United States,” said Lori Davis, M.D., clinical professor of psychiatry in the Department of Psychiatry and Behavioral Neurobiology,
University of Alabama School of Medicine
. “For the first time, we now have data from a comprehensive clinical trial program that show a combination of medicines can help improve the four symptom clusters of
PTSD
as defined by the DSM-5.” Across the three randomized trials, the combination of
brexpiprazole
and
sertraline
in adult patients with
PTSD
were generally well-tolerated, and no new safety observations were identified. The safety and tolerability results were consistent with the known pro
brexpiprazole
in its approved indications and what has been observed in other clinical trials. The overall incidence of treatment-emergent adverse events (TEAEs) across the three trials was 55.5 percent with
brexpiprazole
plus
sertraline
, and 56.2 percent with
sertraline
plus placebo.2 In Trial 061, the least squares mean change from randomization (Week 1) in CAPS-5 total score was -16.4 with
brexpiprazole
in combination with
sertraline
(p=0.011 versus
sertraline
plus placebo), -12.2 with
brexpiprazole
plus placebo, -11.4 with
sertraline
plus placebo, and -10.5 with placebo. In Trial 071, the least squares mean change was -19.2 with
brexpiprazole
in combination with
sertraline
(p=0.0007 versus
sertraline
plus placebo) and -13.6 with
sertraline
plus placebo. In Trial 072, the least mean change was -16.5 with
brexpiprazole
2 mg/day in combination with
sertraline
(p=0.52 versus
sertraline
plus placebo), -18.3 with
brexpiprazole
3 mg/day in combination with
sertraline
(p=0.66 versus
sertraline
plus placebo), and -17.6 with
sertraline
plus placebo.1 “Lack of recognition and misdiagnosis of
PTSD
can result in ineffective management, with the average time from onset of symptoms to treatment being 12 years,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer,
Otsuka
. “These findings represent a remarkable advancement in managing the
PTSD
symptoms of those affected by this chronically misunderstood and prevalent
psychiatric disorder
.” “With approximately 13 million people in the
U.S.
suffering from
PTSD
in a given year, these data are crucial to bringing forward a potential new treatment option,” said Johan Luthman, Ph.D., executive vice president,
Lundbeck
research & development. “We’re hopeful that
brexpiprazole
in combination with
sertraline
can become an approved treatment option for appropriate patients living with
PTSD
.” About CAPS-5 The Clinician-Administered
PTSD
Scale for DSM-5 (CAPS-5) is a structured interview designed to assess
PTSD
diagnostic status and symptoms severity as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). The interview consists of 30 items, with a higher score indicating a worse outcome.4 About
Post-Traumatic Stress Disorder
PTSD
is one of the most common
mental health disorders
in the United States, with approximately five percent of the population affected during a given year.5,6,9-11 It may occur in people who have experienced or witnessed a traumatic event, series of events or set of circumstances. An individual may experience this as emotionally or physically harmful or life-threatening and may affect mental, physical, social, and/or spiritual well-being. Examples include physical/sexual assault, natural disasters, serious accidents, terrorist acts, war/combat, historical trauma, intimate partner violence and bullying.7,12 Symptoms of
PTSD
are generally grouped into four types: intrusion (re-experiencing), avoidance, negative cognitions and mood, and marked alterations in arousal and reactivity.5,8 Symptoms can vary over time or vary from person to person.7 Symptoms usually begin within 3 months of the traumatic incident, but they sometimes emerge later. To meet the criteria for
PTSD
diagnosis, symptoms must last longer than one month, and they must be severe enough to interfere with aspects of daily life, such as relationships or work. Symptoms also must not be due to medications, substance use, or a medical condition.5 Guideline recommended first-line treatment includes psychotherapy (e.g., cognitive behavioral therapy) and first line pharmacotherapy options include certain antidepressants.13 About the Studies Trials 331-201-061 (NCT03033069), 331-201-00071 (NCT04124614) and 331-201-00072 (NCT04174170) were designed to evaluate the efficacy, safety and tolerability of treatment with
brexpiprazole
in combination with
sertraline
in adults with
PTSD
. The trial populations included male and female patients, aged 18-65 years (inclusive), with a diagnosis of
PTSD
according to the DSM-5 and confirmed by the Mini International Neuropsychiatric Interview. The trials consisted of a 1-week double-blind placebo run-in period followed by 11 weeks of double-blind randomized treatment for a continuous 12-week double-blind treatment period with a 21-day follow-up. Trial 331-201-061 was a 4-arm, double-blind, flexible-dose trial in which patients were randomized to receive flexible-dose
brexpiprazole
1-3 mg/day plus
sertraline
100-200 mg/day, flexible-dose
brexpiprazole
1-3 mg/day plus placebo, flexible-dose
sertraline
100-200 mg/day plus placebo, or placebo (double dummy) during the 11-week randomized treatment period. Trial 331-201-00071 was a 2-arm, double-blind, flexible-dose trial in which patients were randomized to receive either flexible-dose
brexpiprazole
2-3 mg/day plus
sertraline
150 mg/day or
sertraline
150 mg/day plus placebo during the 11-week randomized treatment period. Trial 331-201-00072 was a 3-arm, double-blind, fixed-dose trial in which patients were randomized to receive either fixed-dose
brexpiprazole
2 mg/day plus
sertraline
150 mg/day,
brexpiprazole
3 mg/day plus
sertraline
150 mg/day, or
sertraline
150 mg/day plus placebo during the 11-week randomized treatment period. The primary outcome in all trials was the change from randomization to week 10 in the CAPS-5 total score; in Trials 331-201-00071 and 331-201-00072 patients had to meet blinded criteria at the week 1 visit of the trial.4 About
Brexpiprazole
Brexpiprazole
was approved in the
U.S.
in 2015, as an adjunctive therapy to antidepressants in adults with
MDD
and as a treatment for
schizophrenia
in adults. Most recently,
brexpiprazole
was approved in the
U.S.
for the treatment of agitation associated with
dementia
due to
Alzheimer's disease
, in May 2023.
Brexpiprazole
was also approved by Health Canada for
schizophrenia
and adjunctive treatment of
MDD
in 2017 and 2019, respectively. It was approved by the
Ministry of Health, Labour and Welfare
in Japan and by the
European Medicines Agency
in 2018 for the treatment of
schizophrenia.3
Brexpiprazole
was discovered by
Otsuka
and is being co-developed by
Otsuka
and
Lundbeck
. The mechanism of action of
brexpiprazole
is unknown.
Brexpiprazole
has high receptor binding affinity to norepinephrine, serotonin and
dopamine receptors
. It is an antagonist at norepinephrine α1B and α2C receptors and
serotonin 5-HT2A receptors
, as well as a partial agonist activity at
serotonin 5-HT1A
and dopamine D2 receptors.14,15 INDICATIONS and IMPORTANT SAFETY INFORMATION for
REXULTI
® (
brexpiprazole
) INDICATIONS:
REXULTI
is a prescription medicine used to treat:
Major depressive disorder (MDD)
:
REXULTI
is used with antidepressant medicines, when your healthcare provider determines that an antidepressant alone is not enough to treat your
depression
. Schizophrenia It is not known if
REXULTI
is safe and effective in people under 18 years of age. IMPORTANT SAFETY INFORMATION: Increased risk of death in elderly people with
dementia-related psychosis
. Medicines like
REXULTI
can raise the risk of death in elderly who have lost touch with reality (
psychosis
) due to
confusion
and
memory loss
(
dementia
).
REXULTI
is not approved for the treatment of patients with
dementia-related psychosis
. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment.
Depression
and other serious
mental illnesses
are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions. Patients on antidepressants and their families or caregivers should watch for new or worsening
depression
symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. Report any changes in these symptoms immediately to the doctor.
REXULTI
is not approved for the treatment of people younger than 18 years of age. Contraindication: Do not take
REXULTI
if you are allergic to
brexpiprazole
or any of the ingredients in
REXULTI
.
Allergic reactions
have included
rash
,
facial swelling
,
hives
and
itching
, and
anaphylaxis
, which may include
difficulty breathing
, tightness in the chest, and
swelling
of the mouth, face, lips, or tongue.
REXULTI
may cause serious side effects, including:
Stroke
in elderly people (cerebrovascular problems) that can lead to death.
Neuroleptic Malignant Syndrome (NMS)
: Tell your healthcare provider right away if you have some or all of the following symptoms:
high fever
,
stiff muscles
,
confusion
, sweating, changes in pulse, heart rate, and blood pressure. These may be symptoms of a rare and serious condition that can lead to death. Call your healthcare provider right away if you have any of these symptoms. Uncontrolled body movements (tardive dyskinesia).
REXULTI
may cause movements that you cannot control in your face, tongue or other body parts.
Tardive dyskinesia
may not go away, even if you stop taking
REXULTI
.
Tardive dyskinesia
may also start after you stop taking
REXULTI
. Problems with your metabolism such as: high blood sugar (hyperglycemia): Increases in blood sugar can happen in some people who take
REXULTI
. Extremely high blood sugar can lead to
coma
or death. If you have
diabetes
or risk factors for
diabetes
(such as being overweight or having a family history of
diabetes
), your healthcare provider should check your blood sugar before you start taking
REXULTI
and during your treatment. Call your healthcare provider if you have any of these symptoms of high blood sugar while taking
REXULTI
: feel very thirsty feel very hungry feel sick to your stomach feel weak or tired need to urinate more than usual feel confused, or your breath smells fruity increased fat levels (cholesterol and triglycerides) in your blood. weight gain. You and your healthcare provider should check your weight regularly. Low white blood cell count Decreased blood pressure (
orthostatic hypotension
). You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.
Seizures
(convulsions) Problems controlling your body temperature so that you feel too warm. Avoid getting over-heated or dehydrated while taking
REXULTI
. Do not over-exercise. Stay out of the sun. Do not wear too much or heavy clothing. In hot weather, stay inside in a cool place if possible. Drink plenty of water. Difficulty swallowing that can cause food or liquid to get into your lungs. Do not drive a car, operate machinery, or do other dangerous activities until you know how
REXULTI
affects you. REXULTI may make you feel drowsy. Avoid drinking alcohol while taking
REXULTI
. Before taking
REXULTI
, tell your healthcare provider if you: have
diabetes
or high blood sugar or a family history of
diabetes
or high blood sugar. Your healthcare provider should check your blood sugar before you start
REXULTI
and during your treatment. have high levels of cholesterol, triglycerides, LDL-cholesterol, or low levels of HDL cholesterol have or had
seizures
(
convulsions
) have or had low or high blood pressure have or had heart problems or a
stroke
have or had a low white blood cell count are pregnant or plan to become pregnant. It is not known if
REXULTI
may harm your unborn baby. Using
REXULTI
in the last trimester of pregnancy may cause
muscle movement problems
, medicine withdrawal symptoms, or both of these in your newborn. If you become pregnant while taking
REXULTI
, talk to your healthcare provider about registering with the National Pregnancy Registry for
Atypical Antipsychotics
. You can register by calling 1-866-961-2388 or visit are breastfeeding or plan to breastfeed. It is not known if
REXULTI
passes into your breast milk. You and your healthcare provider should decide if you will take
REXULTI
or breastfeed. Tell your healthcare provider about all the medicines you take or recently have taken, including prescription medicines, over-the-counter medicines, vitamins and herbal supplements.
REXULTI
and other medicines may affect each other causing possible serious side effects.
REXULTI
may affect the way other medicines work, and other medicines may affect how
REXULTI
works. Your healthcare provider can tell you if it is safe to take
REXULTI
with your other medicines. Do not start or stop any medicines while taking
REXULTI
without talking to your healthcare provider first. The most common side effects of
REXULTI
include weight gain and an inner sense of restlessness such as feeling like you need to move. Tell your healthcare provider if you experience
abnormal muscle spasms
or contractions, which may be a sign of a condition called
dystonia
. These are not all the possible side effects of
REXULTI
. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about your health or medicines, including side effects. You are encouraged to report side effects of
REXULTI
(
brexpiprazole
), please contact
Otsuka America Pharmaceutical, Inc.
at 1-800-438-9927 or
FDA
at 1-800-FDA-1088 ( ). Please read
U.S.
FULL PRESCRIBING INFORMATION, including Boxed WARNING, and Medication Guide, for
REXULTI
About
Otsuka
Otsuka Pharmaceutical Co., Ltd.
is a global healthcare company with the corporate philosophy:
Otsuka
–people creating new products for better health worldwide.
Otsuka
researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals,
Otsuka
is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in
oncology
and on several under-addressed diseases including
tuberculosis
, a significant global public health issue. These commitments illustrate how
Otsuka
is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka
established a presence in the
U.S.
in 1973 and today its
U.S.
affiliates include
Otsuka Pharmaceutical Development & Commercialization, Inc.
(OPDC) and
Otsuka America Pharmaceutical, Inc.
(
OAPI
). These two companies’ 2,250 employees in the
U.S.
develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and
OAPI
are indirect subsidiaries of
Otsuka Pharmaceutical Co., Ltd.
, which is a subsidiary of
Otsuka Holdings Co., Ltd.
headquartered in Tokyo, Japan. The
Otsuka group
of companies employed 34,400 people worldwide and had consolidated sales of approximately USD 14.2 billion in 2023. All
Otsuka
stories start by taking the road less traveled. Learn more about
Otsuka
in the
U.S.
at and connect with us on LinkedIn and Twitter at @OtsukaUS.
Otsuka Pharmaceutical Co., Ltd.
’s global website is accessible at . About
Lundbeck
Lundbeck Pharmaceuticals LLC is a wholly owned US subsidiary of
H. Lundbeck A/S
(HLUNa / HLUNb, HLUNA DC / HLUNB DC), a global biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with
neurological and psychiatric diseases
. As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of. Too many people worldwide live with
brain diseases
– complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with
brain diseases
and advocating for broader social acceptance of people with brain health conditions. Every day, we strive for improved treatment and a better life for people living with
brain disease
. We have approximately 5,700 employees, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for
brain diseases
for which there are few, if any therapeutic options. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy.
Lundbeck US
comprises the wholly owned US subsidiaries of
H. Lundbeck A/S
, including
Lundbeck LLC
and Lundbeck Pharmaceuticals LLC. With a workforce of more than 1,000 colleagues,
Lundbeck US
is deeply committed to enhancing the lives of patients, families, and caregivers through focused innovation in neuroscience. For additional information, please visit Lundbeck.com/us and connect with us on LinkedIn and X at @LundbeckUS. References Behl S et al. Efficacy of
Brexpiprazole
in Combination with
Sertraline
for Patients with
Post-Traumatic Stress Disorder
: Summary of Data from Phase 2 and Phase 3 Randomized Clinical Trials. Presented at ASCP 2024 (May 28-31). Behl S et al. Safety and Tolerability of
Brexpiprazole
in Combination with
Sertraline
for Patients with
Post-Traumatic Stress Disorder
: Summary of Data from Phase 2 and Phase 3 Randomized Clinical Trials. Presented at ASCP 2024 (May 28-31). Otsuka. Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of
Brexpiprazole
as Combination Therapy with
Sertraline
for the Treatment of
Post-Traumatic Stress Disorder
in Adults. Last accessed: May 20, 2024. Available at: . Behl, S. Clinical Program of
Brexpiprazole
in Combination with
Sertraline
for Patients with
Post-Traumatic Stress Disorder
. Panel presentation at ASCP May 28, 2024. Lancaster CL, Teeters JB, Gros DF, Back SE.
Posttraumatic Stress Disorder
: Overview of Evidence-Based Assessment and Treatment. J Clin Med. 2016;5(11):105. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H -U. Twelve-month and lifetime prevalence and lifetime morbid risk of
anxiety and mood disorders
in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013. Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC. Failure and delay in initial treatment contact after first onset of
mental disorders
in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):603-613. U.S. Department of Veterans Affairs. How Common Is
PTSD
in Adults? Last updated: Feb. 3, 2023. Last accessed: April 30, 2024. Available at: . US Census Bureau 2022 Data. Lehavot K, Katon JG, Chen JA, Fortney JC, Simpson TL.
Post-traumatic Stress Disorder
by Gender and Veteran Status [published correction appears in Am J Prev Med. 2019 Oct;57(4):573]. Am J Prev Med. 2018;54(1):e1-e9. American Psychiatric Association. What is
Posttraumatic Stress Disorder (PTSD)
? Last updated: November 2022. Last accessed: April 30, 2024. Available at: . VA/DoD Clinical Practice Guideline for Management of
PTSD
– Provider Summary 2023. Version 4.0. US Department of Veterans Affairs, US Department of Defense; 2023. Last accessed May 22, 2024. . Maeda K, Sugino H, Akazawa H, et al.
Brexpiprazole
I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589-604.
REXULTI
® (
brexpiprazole
). Prescribing Information. FDA. Reference ID: 4911319. May 2023. © 2024 Otsuka America Pharmaceutical, Inc. All Rights Reserved. May 2024 11US24EBC0162
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S
U.S. HealthWorks of New Jersey, Inc.
[+9]
适应症
创伤后应激障碍
精神障碍
行为障碍
[+30]
靶点
DRDs
5-HT2A receptor
5-HT1A receptor
药物
依匹哌唑
盐酸舍曲林
TKP-1002
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务